Sepsis Diagnostics Market Analysis By Product (Instruments, Blood Culture Media, Assay Kits), By Technology (Microbiology, Molecular Diagnostics, Immunoassays), By Testing Type (Laboratory, PoC), By Pathogen, And Segment Forecasts, 2014 - 2025

The global sepsis diagnostics market is expected to reach a value of USD 874.6 million by 2025, according to a new report by Grand View Research, Inc. Rising prevalence of sepsis is the most significant factor anticipated to drive the market growth during the forecast period.

According to the National Center for Biotechnology Information, the number of patients suffering from septic poisoning rose by an average of 5.7% each year. As a result of this, there is a rising need for early diagnosis of such blood-poisoning diseases amongst patients. High prevalence of sepsis is also leading to a huge mortality rate, which is triggering early diagnosis to execute the clinical intervention.

Rising number of hospital-acquired infections are also expected to support the growth of the market over the forecast period. Hospital-acquired infections majorly include urinary tract & surgical site infections, which result into sepsis. According to WHO, 7 out of every 100 hospitalized patients develop hospital-acquired infections in developed countries. Thus, such infections significantly cause septicemia, which will resultantly raise the need for early diagnosis. On the other hand, pneumonia is also an important driving factor for high demand of sepsis diagnostics as it is one of the major causes for septic shock.

Further key findings from the study suggest:

Blood culture media was the largest segment in 2015 due to higher adoption of culture media tests in laboratories for the diagnosis of septic poisoning

Molecular diagnostics is anticipated to witness lucrative growth over the forecast period due to quick and efficient identification of microorganisms causing septicemia

Bacterial sepsis contributed toward the largest revenue in 2015. This is due to the fact that bacterial infection is the most common cause for people suffering from septic poisoning

In 2015, laboratory testing segment held the highest share due to the fact that majority of the sepsis diagnostic tests are being conducted in laboratory-based setting

North America dominated in 2015 owing to the increasing mortality rate of patients suffering from septicemia

Some of the key companies include bioMerieux SA, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Roche Diagnostics, Cepheid Inc., Beckman Coulter, Inc., Nanosphere, Inc., and Bruker Corporation

Table of Contents

Chapter 1 Research Methodology
1.1 Country Wise Market: Base Estimates
1.2 Global Market: CAGR Calculation
1.3 Region Based Segment Share Calculation
1.4 Research Scope & Assumptions
1.5 List of Data Sources
1.5.1 Data for primary interviews, by sources
1.5.2 Data for primary interviews, by region
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Sepsis Diagnostics Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Increasing prevalence of sepsis
3.2.2 Growing incidence of hospital-acquired infections
3.2.3 Growing number of pneumonia cases
3.3 Market Restraint Analysis
3.3.1 High cost of automated diagnostic instruments
3.3.2 Lack of awareness for sepsis
3.4 Key Opportunities Prioritized
3.4.1 Key opportunities prioritized, by product
3.4.2 Key opportunities prioritized, by technology
3.4.3 Key opportunities prioritized, by pathogen
3.4.4 Key opportunities prioritized, by testing type
3.5 Sepsis Diagnostics - SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
3.6 Industry Analysis - Porter’s
3.7 Sepsis Diagnostics Market: Competitive Analysis, 2015
Chapter 4 Sepsis Diagnostics Market: Product Estimates & Trend Analysis
4.1 Sepsis Diagnostics Market: Product Movement Analysis
4.2 Instruments
4.2.1 Instruments market, 2014 - 2025 (USD Million)
4.3 Blood Culture Media
4.3.1 Blood culture media market, 2014 - 2025 (USD Million)
4.4 Assays Kits & Reagents
4.4.1 Assays kits & reagents market, 2014 - 2025 (USD Million)
Chapter 5 Sepsis Diagnostics Market: Technology Estimates & Trend Analysis
5.1 Sepsis Diagnostics Market: Technology Movement Analysis
5.2 Microbiology
5.2.1 Microbiology market, 2014 - 2025 (USD Million)
5.3 Molecular Diagnostics
5.3.1 Molecular diagnostics market, 2014 - 2025 (USD Million)
5.4 Immunoassays
5.4.1 Immunoassays market, 2014 - 2025 (USD Million)
5.5 Flow Cytometry
5.5.1 Flow cytometry market, 2014 - 2025 (USD Million)
Chapter 6 Sepsis Diagnostics Market: Pathogen Estimates & Trend Analysis
6.1 Sepsis Diagnostics Market: Pathogen Movement Analysis
6.2 Bacterial Sepsis
6.2.1 Bacterial sepsis market, 2014 - 2025 (USD Million)
6.2.2 Gram-negative bacterial sepsis
6.2.2.1 Gram-negative bacterial sepsis market, 2014 - 2025 (USD Million)
6.2.3 Gram-positive bacterial sepsis
6.2.3.1 Gram-positive bacterial sepsis market, 2014 - 2025 (USD Million)
6.3 Fungal Sepsis
6.3.1 Fungal sepsis market, 2014 - 2025 (USD Million)
6.4 Other Pathogenic Sepsis
6.4.1 Other pathogenic sepsis market, 2014 - 2025 (USD Million)
Chapter 7 Sepsis Diagnostics Market: Testing Type Estimates & Trend Analysis
7.1 Sepsis Diagnostics Market: Testing Type Movement Analysis
7.2 Laboratory Testing
7.2.1 Laboratory testing market, 2014 - 2025 (USD Million)
7.3 Point-of-Care Testing
7.3.1 Point-of-care testing market, 2014 - 2025 (USD Million)
Chapter 8 Sepsis Diagnostics Market: Regional Estimates & Trend Analysis, by Product, Technology, Pathogen, Testing Type
8.1 Sepsis Diagnostics Market Share by Region, 2014 & 2025
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.4 Asia Pacific
8.4.1 China
8.4.2 India
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.6 MEA
8.6.1 South Africa
Chapter 9 Competitive Landscape
9.1 Company Profiles
9.1.1 biomerieux SA
9.1.1.1 Company overview
9.1.1.2 Financial performance
9.1.1.3 Product benchmarking
9.1.1.4 Strategic initiatives
9.1.2 Becton, Dickinson and Company
9.1.2.1 Company overview
9.1.2.2 Financial performance
9.1.2.3 Product benchmarking
9.1.3 Thermo Fisher Scientific Inc.
9.1.3.1 Company overview
9.1.3.2 Financial performance
9.1.3.3 Product benchmarking
9.1.3.4 Strategic initiatives
9.1.4 Roche Diagnostics
9.1.4.1 Company overview
9.1.4.2 Financial performance
9.1.4.3 Product benchmarking
9.1.4.1 Strategic initiatives
9.1.5 Cepheid Inc.
9.1.5.1 Company overview
9.1.5.2 Financial performance
9.1.5.3 Product benchmarking
9.1.6 Beckman Coulter, Inc.
9.1.6.1 Company overview
9.1.6.2 Product benchmarking
9.1.6.3 Strategic initiatives
9.1.7 Nanosphere, Inc.
9.1.7.1 Company overview
9.1.7.2 Product benchmarking
9.1.8 Bruker Corporation
9.1.8.1 Company overview
9.1.8.2 Financial performance
9.1.8.3 Product benchmarking
9.1.8.4 Strategic initiatives